We previously reported genetic linkage of loci controlling age-at-onset in Alzheimer disease (AD) and Parkinson disease (PD) to a 15 cM region on chromosome 10q.
INTRODUCTION
Genetic studies of common complex diseases such as Alzheimer disease ( AD; MIM 104300) and Parkinson disease (PD; MIM 168600) have focused on identifying risk genes as targets for developing new treatments and improved diagnoses. This approach led to the identification of several genes contributing to risk in either AD or PD (1, 2) .
However, risk is only one mode of genetic expression; age-at-onset of AD and PD is also genetically controlled (3, 4) . Identifying genes that control age-at-onset may allow therapeutic intervention to delay disease onset beyond the natural lifespan. The present study looks specifically at genes that affect age-at-onset in these two neurodegenerative disorders, not genes that affect the risk of developing the disease.
We previously reported the first genetic linkage screen for age-at-onset in AD and PD and identified several chromosomal regions that may harbor novel age -at-onset genes.
The most interesting finding was a ~15cM linkage region surrounding D10S1239 and D10S1237 on chromosome 10q (Fig. 1 ). This linkage region was found in both AD and PD families (4) , suggesting the existence of a common gene affecting age-at-onset in both disorders. Here, we follow up the chromosome 10q region to search for novel ageat-onset genes for AD and PD.
This linkage peak is large, spanning over 15 megabases. Thus an effective method is needed to narrow the number of genes for further study. We have previously reported the concept of "genomic convergence" (5) to prioritize the evaluation of candidate genes.
This approach converges the results of two or more different genomic techniques, with the premise that genes shown significant in several kinds of tests have a higher likelihood of being important in the disease process. In this study, we hypothesized that genes demonstrating significant differences in expression level between AD and control hippocampus may play a potential role as disease modifiers or disease susceptibility genes. We used AD gene expression study as our second convergence factor, combined with our previously reported linkage data for age-at-onset (not risk), to select candidate genes that modify the age -at-onset of AD.
Convergence identified four candidate genes mapping to the chromosome 10q linkage region: Stearoyl-CoA desaturase (SCD; MIM 604031); NADH-ubiquinone oxidoreductase 1 beta complex 8 (NDUFB8; MIM 602140); glutathione S-transferase, omega-1 (GSTO1, also called GSTO1-1; MIM 605482); and protease, serine 11 (PRSS11; MIM 602194). Upon further evaluation we identified a second actively transcribed member of the glutathione transferase omega class, GSTO2, which lies 7.5kb downstream of GSTO1 (6) and was not included in the arrays used in the study. GSTO2 has 64% amino acid identity with GSTO1. These five genes (SCD, NDUFB8, GSTO1, GSTO2, and PRSS11), therefore, become excellent candidate genes to evaluate for a role in the control of age-at-onset in AD and PD. Using single nucleotide polymorphisms (SNPs), association analysis (an approach independent of the gene expression study) was performed for each gene to test the relationship between the markers and age -at -onset in AD and PD.
RESULTS
Candidate Genes: Eight GeneChips (Affymetix), one array per sample, were used to test probes for about 22,000 predicted or known human genes. After applying initial filtering criteria to exclude the genes with low signal intens ity, 1072 genes remained for further analysis. Fifty-two genes demonstrated significant differences in gene expression levels between AD and controls. Four of these genes (SCD, NDUFB8, GSTO1, and PRSS11) map to the chromosome 10q linkage region. The average raw signal intensity and its standard deviation for AD and control samples are listed in Table 3 . Clearly, the transcripts of these four genes were significantly down-regulated in AD in comparison to controls. Figure 1 depicts the genomic locations of these genes relative to D10S1239, D10S1237, and our linkage peaks for PD and AD. Among them, GSTO1 is located under the linkage peak (LOD=2.62) of the combined AD and PD dataset (4). Lying 7.5kb downstream of GSTO1 is GSTO2, which was not on the Affymetrix GeneChip U133A array.
Association Study:
We initially genotyped 18 SNPs spanning these five candidate genes in the 1773 AD patients and 1041 relatives. All SNPs were in HWE. Strong linkage disequilibrium (LD; r 2 > 0.85) was seen between two pairs of SNPs in the GSTO1 and GSTO2 region (SNP7 and SNP9, SNP8 and SNP11) as well as between SNP15 and SNP17 in PRSS11 (Table 3 ). Other SNPs were in strong LD neither with each other nor with any SNPs located in GSTO1, GSTO2 or PRSS11, indicating that the glutathione Stransferases and PRSS11 form two independent LD groups.
Age -at-onset was analyzed as a quantitative trait. The mean age -at-onset ± SD was 72±8 SNP7 (Ala140Asp) in GSTO1 creates a non-conservative amino acid change from a hydrophobic to a hydrophilic resid ue. The MK method detected that the less common asparagine (Asp) allele for GSTO1 SNP7 and the -183C allele for GSTO2 SNP9 are associated with later age -at-onset for both AD and PD. The inclusion of APOE as a covariate had little effect on the association results (p-values remained similar for each SNP), suggesting that the association between the SNPs and age -at-onset is independent from any APOE effect.
DISCUSSION
The convergence of genetic linkage, gene expression, and association studies showed that SNPs in GSTO1 and GSTO2 are associated with age-at-onset in AD and PD. We chose SNPs with similar spacing (approximately 5kb) across all genes. Although extensive SNP detection and genotyping are always the best choice, the availability of the SNPs and cost considerations are the barriers to such an approach. Here, we have used a reasonable density of SNPs for each gene. Although SNP18 in PRSS11 was significantly associated with age-at-onset in the AD dataset by the OM method, the overall evidence was not strong enough to conclude that PRSS11 is associated with age-at-onset of AD and PD.
This is interesting given this gene has the lowest p-value in the gene expression study.
The p-value could, however, reflect only secondary changes of cell loss. Overall, the genomic convergence approach proposed here allows us to obtain more meaningful candidates than a single method alone.
The similar association pattern seen with age -at-onset in SNP7 (GSTO1) and SNP9 (GSTO2) would appear to be due to the strong LD between these two SNPs. The pairwise LD estimations revealed three pairs of markers (SNP7 and SNP9, SNP8 and SNP11, and SNP15 and SNP17) in strong LD (r 2 > 0.85), which led to similar association results. The
SNPs in GSTO1 and GSTO2 are not in LD with those in SCD, NDUFB8, and PRSS11.
No LD structure was found in SCD or most of PRSS11. Furthermore, we did not detect any association between the SNPs genotyped in these three genes (SCD, NDUFB8, and PRSS11) and age-at-onset. Based on the pattern of LD structure and association results, we believe that the region in GSTO1 and GSTO2 flanked by SNP7 and SNP9 is the primary candidate region for a susceptibility allele for age-at-onset in AD and PD.
While our current study focused on genes relating to age -at-onset, we also examined whether these genes might contribute to risk of developing AD or PD. We tested GSTO1
and GSTO2 for risk in AD and PD by using the pedigree disequilibrium test (PDT) (7), in which the disease phenotype is the trait of interest. There was no evidence for allelic association of any of the SNP s with risk of developing either disease. Since our datasets are relatively large (711 families in AD and 298 in PD), we believe that the PDT method has enough power to detect the risk effect if present, according to the power study in
Martin et al. (7) . The effect of GSTO1 thus appears to be specific to age-at -onset as is implied by our previously reported linkage results.
In the genomic convergence approach, whether a gene is over-or under-expressed in the disease tissue is not important, nor is the level of significance. Rather, importance is placed on whether a gene has any significant difference in expression levels, suggesting it has the potential to be involved in the disease process. Certainly, genes demonstrating expression changes between these two sample groups may be involved in primary or secondary pathways of disease. One of the great challenges with expression analyses is the sheer numbers of genes demonstrating differences and the complex interactions that lead to these differences. Placing importance on over or under-expression can often be misleading, without a complete understanding of the biological processes involved. In our approach, those genes with significant expression differences between control and disease tissue that also lie within the independently determined age-at-onset linkage regions have an increased likelihood to control age-at-onset. These "converged" genes can then be tested for genetic association with age-at-onset, an analysis independent of their expression changes and the genetic linkage results. When converged genes subsequently demonstrate significant genetic association with age -at-onset, the likelihood that they play an important role in the primary disease processes greatly increases.
GSTO1 is a member of the glutathione S-transferase (GST) family of genes that utilize glutathione in reactions and contribute to the biotransformation and disposition of many compounds, including drugs, carcinogens, and the products of oxidative stress. GSTO1
is expressed in a wide range of tissues, specifically neural glial cells (8) . GSTO1 is unusual in that it has a different substrate profile than other members of this family, Recently, it was demonstrated that the activity of the Asp allele of SNP7 in GSTO1 (10) responds differently from the Ala allele depending on the substrate provided, further strengthening the hypothesis that this SNP has functional significance in AD and PD.
SNP9 is 183 bp upstream of exon 1 of GSTO2, and could conceivably have an effect on this gene's promoter. However, the lack of association with SNP10 and SNP11, located in intron 3 and exon 4 of GSTO2, and the strong LD between SNP7 and SNP9 support the hypothesis that GSTO1, rather than GSTO2, is the primary candidate gene affecting age-at-onset of AD and PD. However, further investigation will be needed to solidify this point.
Recently reported work (11) provides the most exciting potential mechanism for the GSTO1 effect we have observed on age -at-onset. Laliberte et al. (11) report that current experimental drugs at Pfizer known as cytokine release inhibitory drugs, which inhibit interleukin-1ß (IL-1ß ) posttranslational processing, have GSTO1 as their direct target.
This implies that GSTO1 may be involved in the activation of IL-1ß, and thus variation in GSTO1 could alter the efficacy of IL-1ß post-translational processing, modulating an inflammatory response. IL-1ß is a fundamental component in inflammatory response, a mechanism that has been suggested as contributing to the pathogenesis of both AD and PD (12) (13) (14) (15) . Indeed, several studies have suggested that IL-1ß is over-expressed in AD and PD brains (12, 13) , and is induced by the amyloid Aß peptide (16) .
In summary, association of GSTO1 and possibly GSTO2 with age-at-onset for both AD and PD has been demonstrated. This continues to support the premise that AD and PD pathogenesis share many common mechanisms. The confluence of this GSTO1 association with previous findings demonstrates genomic convergence as a sensitive and viable approach for the genetic mapping of complex diseases. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. To label the RNA for hybridization to the microarray chip, 7 µg of total RNA were used for double -stranded cDNA synthesis using the SuperScript Choice System (Gibco BRL Life Technologies, Rockville, MD) in conjunction with a T7-(dT)-24 primer (Geneset Oligos, La Jolla, CA). The cDNA was purified using Phase Lock Gel (5 Prime ?3 Prime, Inc., Boulder, CO). In vitro transcription was performed to produce biotin-labeled cRNA using a BioArray HighYield RNA Transcript Labeling Kit (Affymetrix, Santa Clara, CA) according to the manufacturer's instruc tions. The biotinylated cRNA was cleaned using the RNeasy Mini kit (Qiagen, Valencia, CA) (19, 20) .
MATERIALS AND METHODS

RNA isolation and preparation for hybridization:
Hybridization to high density oligonucleotide microarrays : 20 µg of biotinylated cRNA was fragmented and hybridized at 45°C for 16-18 hours using Affymetix Human Genome U133A arrays (Affymetrix Inc., Santa Clara, California), in which about 22,000 genes were spotted. After being washed, the array was stained and amplified as described (19) and scanned on an HP Gene Array Scanner (Affymetrix Inc., Santa Cala ra, California). The intensity for each feature was captured with Affymetrix Microarray Suite 5.0 software, according to standard Affymetrix procedures by performing global scaling with an average "target intensity" of 100 for all probe sets.
For quality control, RNA samples were checked by Northern blotting (28S, 18S, and 260/280 ratio) and judged to be of high quality prior to use. All arrays were visually inspected to identify arrays with production defects. To control for partial RNA degradation, 3'/5' end ratios for the housekeeping genes actin and GAPDH were examined. Arrays with high 3'/5' end ratios (>5) suggestive of partial RNA degradation were excluded from further analysis.
Microarray Data Analysis:
Since genes with low signal intensity often cause high variability between arrays and Northern blots usually do not confirm positive results for genes with signal intensity less than 500, only genes with average expression intensities of =500 were considered for further analysis. Log 2 (logarithm base 2) was used for data normalization, so data within each chip are in agreement with a normal distribution. A two-sample t-test was used to calculate the nominal p-value to test whether the gene expression between case and control groups was significantly different. In addition, disease status was randomly assigned to each sample 1000 times to estimate an empirical p-value for each gene. A nominal significance level of 0.05 was compared with both nominal and empirical p-values to declare a result significant.
Family data:
The AD dataset includes 606 multiplex and 105 discordant sibpair families.
Clinical diagnosis was based on consensus criteria (21) . At least one individual in each of the 711 families has AD diagnosis of either "definite" (autopsy confirmed) or "probable" (clinically affected without autopsy). The source of families was described in our previous genomic screen study (4) and most families used in present study are the same as in the previous one. Even in early-onset families, carriers of PS1, PS2, and APP mutations are very rare, and such mutations have not been found in intensive screening of late-onset families (22) (23) (24) . The inclusion of these rare early-onset mutation families
should not have much, if any, effect on our results, because we are searching for genes that modulate age-at-onset independently of any underlying risk cause. Age-at-onset for AD patients was defined as the age at which the caregiver, family, and/or individual first noted cognitive problems sufficient to interfere with independent daily activities. The PD dataset consists of 282 multiplex and 16 discordant sibpair families with a total of 635 PD patients. Diagnosis for PD patients followed consensus criteria (25) . Age-at-onset for PD patients was defined as the age at which an affected individual first noticed one of the cardinal signs of PD (25) . All participants or their legal representatives gave informed consent prior to joining the study, and data were collected according to protocols approved by each c ontributing group's institutional review board. SNPs based on the principles of equal density across genes (approximately 1 SNP per 5 kilobase (kb)) and the SNP availability ( Table 2) . Owing to the different size of each gene, the number of SNPs included varies among these five candidate genes. We used a two-step genotyping strategy for the analysis. Given that both AD and PD were linked to this region, we chose the larger dataset (AD) to screen for association, then genotyped those SNPs with positive or suggested association in the PD dataset. Thus we genotyped 18 SNPs for the AD dataset. Ta qman primers and probes were designed for genotyping SNP7 and SNP8 in GSTO1, SNP9-11 in GSTO2, and SNP18 in PRSS11 (Table 2 ). All other SNPs were obtained using assays -on-demand from ABI. Genotyping efficiency ranged between 95-98%. Following our genotyping strategy, SNP7, SNP9, and SNP18
SNP detection and genotyping
were followed up in the PD dataset.
Genomic DNA was extracted from whole blood using the PureGene system (Gentra Systems, Minneapolis, MN) and the SNPs were genotyped using the TaqMan allelic discrimination assay. APOE genotyping was performed as previously described (26, 27 The orthogonal model (OM) (31) , which applies to general pedigrees, was used to test allelic association between each SNP and age-at-onset. To examine the direction of the effect on age-at-onset, the Monks-Kaplan method (MK) was applied, which uses parental and sibpair data only (32) . Owing to the computational intensity of the permutation test, we only computed the empirical p-values for the markers with significant nominal pvalues (< 0.05). For those markers, we performed 10,000 permutations to avoid falsepositive results. We tested for allelic association between all 18 SNPs and age-at-onset in AD. Same approach was used for PD dataset. Although multiple test correction is often suggested, the Bonferroni correction will lead to a very stringent threshold of 0.001 based on a total of 36 tests. Here, we prioritized the markers based on the p-value and the testing methods. The smaller the p-value, the higher the priority of the marker. In addition, a significant marker needs to be confirmed by both MK and OM methods.
Since APOE, particularly the APOE-4 allele, is associated with age-at-onset in AD (1), and more recently in PD (33) , we also perform association analysis by incorporating the number of APOE-4 alleles as a covariate. 
Figure legends
* Average and standard deviation of the raw signal intensity in each group * The nominal P was from a two-sample t-test and the empirical P was from the permutation test. 
